I. To estimate the overall tumor response rate (ORR i.e. complete response [CR]+partial response [PR]) of the combination of FASN inhibitor TVB-2640 (TVB-2640) with paclitaxel and trastuzumab in patients with taxane and trastuzumab-resistant, advanced HER2-positive breast cancer who have had prior exposure to trastuzumab emtansine (T-DMI) in the metastatic breast cancer setting.